The administration of PBMCs from GC patients enhanced tumor cell growth, whereas butyrate inhibited tumor cell growth by inhibiting the expression of immunosuppressive markers, including PD-L1 and IL-10. This evidence concerns the gene CD274 and gastric cancer.